What is Tab Thyronorm (levothyroxine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is Tab Thyronorm?

Tab Thyronorm is a brand name for levothyroxine sodium tablets, a synthetic thyroid hormone (T4) used as replacement therapy for hypothyroidism. It is chemically identical to the thyroxine produced naturally by the human thyroid gland 1.

Composition and Formulation

Thyronorm contains synthetic levothyroxine sodium with the chemical formula C15H10I4NNaO4. The tablets are available in multiple strengths ranging from 25 mcg to 300 mcg, allowing for precise dose titration 1. Each tablet contains inactive ingredients including magnesium stearate, microcrystalline cellulose, colloidal silicon dioxide, and sodium starch glycolate, with various color additives depending on the strength 1.

Clinical Indications

Thyronorm is indicated for:

  • Primary hypothyroidism (thyroid gland failure)
  • Secondary hypothyroidism (pituitary dysfunction)
  • Tertiary hypothyroidism (hypothalamic dysfunction)
  • Adjunct therapy in thyroid cancer for TSH suppression after surgery and radioiodine therapy 1

Dosing Principles

The levothyroxine requirement is highly individualized based on several factors 2:

For overt hypothyroidism in young healthy adults:

  • Full replacement dose: approximately 1.6 mcg/kg of ideal body weight daily (typically 75-100 mcg for women, 100-150 mcg for men) 2
  • Can start with full replacement dose immediately 2

For patients over 50-60 years without coronary disease:

  • Start with 50 mcg daily 2

For patients with known coronary heart disease:

  • Start with 12.5-25 mcg daily to avoid precipitating angina 2

For subclinical hypothyroidism:

  • Lower doses of 25-75 mcg daily are typically sufficient 2
  • A practical approach: 25 mcg for TSH 4.0-8.0 mIU/L, 50 mcg for TSH 8-12 mIU/L, and 75 mcg for TSH >12 mIU/L 2

Administration Guidelines

Optimal absorption requires specific timing 2:

  • Take with water 30-60 minutes before breakfast on an empty stomach, OR
  • Take at bedtime 4 hours after the last meal
  • Consistency in timing is crucial for stable absorption

Storage requirements:

  • Store at 20-25°C (68-77°F)
  • Protect from light and moisture 2

Common Pitfalls and Drug Interactions

Many substances interfere with levothyroxine absorption 2:

  • Proton pump inhibitors and H2 blockers (though recent short-term studies suggest minimal clinical impact) 2
  • Iron supplements, calcium carbonate, aluminum-containing antacids
  • Soy products, dietary fiber, coffee
  • Enteral feeding formulations

Critical point: If absorption issues are suspected, consider switching to liquid or softgel formulations, which have better bioavailability in malabsorptive conditions 3, 4, 5.

Monitoring and Therapeutic Goals

For primary hypothyroidism:

  • Monitor TSH every 4-8 weeks after dose changes until stable 2
  • Target TSH: within normal reference range (typically 0.4-4.0 mIU/L)
  • Once stable, check TSH annually 2

Special consideration for pregnancy:

  • TSH goal <2.5 mIU/L in first trimester, <3.0 mIU/L in second trimester, <3.5 mIU/L in third trimester 2
  • Monitor every 4 weeks during first half of pregnancy 2
  • Levothyroxine requirements typically increase 30-50% during pregnancy 6

Brand Switching Considerations

Recent evidence suggests that switching between levothyroxine brands (including Thyronorm, Eltroxin, and Lethyrox) is generally safe, with 78% of patients maintaining normal TSH levels without dose adjustment after switching 7. However, TSH monitoring 6-8 weeks after any brand switch is prudent.

Important Warnings

Overtreatment risks include:

  • Atrial fibrillation (especially in elderly)
  • Accelerated bone loss (particularly in postmenopausal women)
  • Cardiovascular complications 2

Contraindications for use:

  • Desiccated thyroid hormone should NOT be used in preference to levothyroxine monotherapy 2
  • Levothyroxine is NOT indicated for weight loss in euthyroid individuals (produces only modest 1.4 kg weight loss when correcting hypothyroidism) 8
  • NOT indicated for benign thyroid nodules in iodine-sufficient patients 1

References

2
Guideline

clinical practice guidelines for hypothyroidism in adults: cosponsored by the american association of clinical endocrinologists and the american thyroid association.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2012

3
Research

Levothyroxine absorption in health and disease, and new therapeutic perspectives.

European review for medical and pharmacological sciences, 2014

Related Questions

What is the appropriate levothyroxine (Hetrazan) dosing regimen for an adult patient?
A patient on levothyroxine 0.2 mg daily and solifenacin 5 mg daily is gaining weight; what medication adjustments should be made?
When should I recheck my thyroid‑stimulating hormone (TSH) level after switching levothyroxine (brand) – at four weeks or six weeks?
Can I drink a 5.5‑ounce serving of V8 juice three hours after taking levothyroxine (Synthroid)?
In a patient with hypothyroidism who is taking levothyroxine 150 µg tablets and is currently vomiting, how should the levothyroxine be managed?
Am I a candidate for lung volume reduction surgery (LVRS)?
What drug class does Baxdrostat belong to, and what are the recommended dosing and maximum dose for patients with chronic kidney disease?
In patients with hypopituitarism, especially older adults, how does the condition increase fall risk and what hormonal replacement and fall‑prevention measures should be implemented?
What are the recommended aliquot volumes and monitoring guidelines for administering blood product transfusions (red cells, platelets, plasma) in infants?
When should a pharmacist refer a patient with dermatitis to a prescriber for further medical evaluation?
In a 23‑week pregnant woman with multiple T2‑hyperintense liver lesions (a 1.7 cm lesion in the left hepatic lobe and two lesions up to 1.3 cm in the posterior right hepatic lobe) on abdominal MRI, what are the recommended next steps for evaluation and management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.